About tbcr
Manuscript Submission
AME Editing Service
Reprint & Permission
Advertising
Contact us
-
General editorial enquiries:
Email: tbcr@amegroups.com -
Copyright related enquiries:
Email: permissions@amegroups.com -
Commercial sales contact (reprints, advertising, etc.):
Email: sales@amegroups.com
Case Report
Translational Breast Cancer Research
2024;
5:
8
(31 January 2024)
Case Report
Translational Breast Cancer Research
2024;
5:
7
(31 January 2024)
Brief Report
Translational Breast Cancer Research
2024;
5:
6
(31 January 2024)
Editorial Commentary
Translational Breast Cancer Research
2024;
5:
5
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
4
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
3
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
2
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
1
(31 January 2024)
Case Report
Translational Breast Cancer Research
2023;
4:
33
(31 October 2023)
Editorial
Translational Breast Cancer Research
2023;
4:
32
(31 October 2023)
Editorial
Translational Breast Cancer Research
2023;
4:
31
(31 October 2023)
Review Article
Translational Breast Cancer Research
2023;
4:
30
(31 October 2023)
Review Article
Translational Breast Cancer Research
2023;
4:
29
(31 October 2023)
Review Article
Translational Breast Cancer Research
2023;
4:
28
(31 October 2023)
Original Article
Translational Breast Cancer Research
2023;
4:
27
(31 October 2023)
Original Article
Translational Breast Cancer Research
2023;
4:
26
(31 October 2023)
Case Report
Translational Breast Cancer Research
2023;
4:
25
(31 July 2023)
Mini-Review
Translational Breast Cancer Research
2023;
4:
24
(31 July 2023)
Review Article
Translational Breast Cancer Research
2023;
4:
23
(31 July 2023)
Review Article
Translational Breast Cancer Research
2023;
4:
22
(31 July 2023)
Case Report
Review Article